Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - a case study
|
|
- Cory Knight
- 5 years ago
- Views:
Transcription
1 24 th Interphex, Japan, Technical conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - a case study
2 Lonza overview Life sciences driven company Headquartered in Basel (Switzerland) Sales of CHF billion in 2010 Global operations: 28 production and R&D facilities Employs over 8,200 people Global leader in custom manufacturing: Active pharmaceutical ingredients both chemical and biological Cell therapy Leading positions in product market niches: Endotoxin detection Cell-based research products Nutrition Ingredients Microbial control products Performance intermediates slide 2
3 Lonza 2010 Business portfolio composition Custom Manufacturing 38% Chemical Manufacturing, Biological Manufacturing, Development Services 8% Life Sciences Portfolio 90% 54% Bioscience Therapeutic Cell Solutions, Testing Solutions, Research Solutions Life Science Ingredients Nutrition Ingredients, Microbial Control, Performance Intermediates slide 3
4 Our complete offering allows us to meet the diverse needs of our customers Technologies Locations Products & Experience Mammalian Cell Culture Microbial Biopharma (parenteral grade) Microbial Fermentation Cell Therapy, Viral Manufacturing & Custom Media Advanced Chemical Synthesis Peptides Synthesis Slough, UK Portsmouth, NH (USA) Porriño, Spain Singapore Visp, Switzerland Hopkinton, MA (USA) Kouřim, Czech Republic Visp, Switzerland Walkersville, MD (USA) Houston, TX (USA) Verviers, Belgium Singapore Visp, Switzerland Nansha, China Braine l Alleud, Belgium Visp, Switzerland Nansha, China Monoclonal antibodies Therapeutic proteins Therapeutic proteins Antibody fragments Vaccines (recombinant & attenuated) Plasmid DNA Recombinant peptides Non-parenteral fermented ingredients Therapeutic proteins (oral & topical) Metabolites (fermentation derived) Industrial enzymes Cell-based therapeutics Viral vaccines & gene therapies Custom liquid and powdered media & buffers UltraPAK bioprocess containers Synthetic therapeutic small molecules (GMP/ISO) Highly Potent APIs Antibody drug conjugates Small molecules (biotransformation) MicroReactor technology Synthetic peptides 28-Oct-11 slide 4
5 Our biologics facilities, products and services are global and leading-edge Hopkinton, MA (USA) Microbial Biopharma 40L to 2,800L cgmp Process R&D Services Slough (UK) Mammalian Cell Culture 200L to 2,000L cgmp Process R&D Services Visp (Switzerland) Microbial Biopharma 20L to 15,000L cgmp Process R&D services Portsmouth, NH (USA) Mammalian Cell Culture 1,500L to 20,000L cgmp Houston Walkersville Houston, TX (USA) Viral Vaccines & Vectors 10L to 2,000L cgmp Process R&D Services Walkersville, MD (USA) Cell Therapy Autologous & Allogeneic Cell Bioassays & Reagents Process R&D Services Media Custom Media & Buffers Bioprocess Containers Hopkinton Portsmouth Slough, UK Verviers, BE Porriño, SP Verviers (Belgium) Cell Therapy Autologous & Allogeneic Cell Bioassays, Reagents Process R&D Services Media Custom Media & Buffers Bioprocess Containers Porriño (Spain) Mammalian Cell Culture 4 x 10,000L cgmp Visp, CH Kouřim, CZ Microbial Fermentation Process R&D Services Kouřim (Czech Republic) Microbial Fermentation 75L to 75,000L cgmp Process R&D Services Tuas Singapore Mammalian Cell Culture 200L to 20,000L cgmp Process R&D Services Cell Therapy Autologous & Allogeneic Cell Bioassays & Reagents Process R&D Services Singapore 28-Oct-11 slide 5
6 slide 6 We offer a full range of development and cgmp manufacturing services Discovery Development Manufacture Distribution basic research disease discovery drug discovery drug development clinical trials production packaging marketing sales distribution pre-development screening cell line construction cgmp cell banking lab supply clinical supply process development scale up launch supply in- market supply cgmp manufacturing support for regulatory submissions
7 Complexity by molecular weight Chemical Molecule Peptide Protein Antibody Cell / Tissue Increasing Molecular Weight (MW) Aspirin (180 Da) 6mer (804 Da) Lysozyme (14,700 Da) Immunoglobulin G (150,000 Da) Surface of an Animal Cell 28-Oct-11 slide 7
8 Mammalian biologics: Client base and operations From small biotech to large pharma US, EU, Japan, Australia 100+ projects on-going in process development and manufacturing 20+ years of experience in mammalian cell technology MAbs, recombinant proteins slide 8
9 slide 9 Mammalian biologics: Portfolio of services Process development Commercial manufacturing Clinical manufacturing Build to buy Cell line creation Multiple potential points of entry and exit for clients
10 Cell line creation Supported from UK and now Singapore Latest GS TM expression systems and cell lines available CHO K1, NS0 cell types typically used Productivity for MAb s up to 5g/L is typical In-house cell line and expression system development will increase productivity in the future targeting 10g/L in 14 days of fermentation Process can start with just an ed DNA sequence for the product Transfection, clone selection and MCB creation in 30 weeks slide 10
11 Process development Upstream Chemically defined cell culture media, animal component free Laboratory scale bioreactor development proven to scale from 200L through to 20,000L Productivity increased through fed-batch culture and precisely controlled operating conditions Downstream Experience of huge range of chromatography techniques, matrices and filtration technologies Scale up experience to 2.0m columns In-house platform technology development will increase process productivity in the future slide 11
12 Clinical manufacturing Experience from 200L through to 5,000L for early phase clinical supply UK, US, Spain and Singapore sites Stirred tank technology, disposable systems, air-lift Experience from 200L through to 20,000L for late phase clinical supply Appropriate CMC packages supplied to support submissions slide 12
13 Commercial manufacturing Commercially licenced products are made in UK, US, ES and once completed, Singapore Successful inspection history for US FDA, EU EMEA, Japanese PMDA plus many more Variety of scales offered 500L through to 20,000L CMC support provided for BLA, EMEA submission Documentation, process validation packages, process support slide 13
14 slide 14 Build to buy Lonza organises the construction, start up, validation, operation and licensing of a new facility Lonza to design facility. Emphasis on leveraging Lonza s existing processes, equipment, design and operation (both technical and quality) for speed and cost benefit Customer platform process can be part of design basis Facility purchase price is fixed Lonza profit based on milestone achievement through to regulatory approval
15 slide 15 Technology transfer experience Between the mid 90 s and the end of 2010, Lonza UK has had experience of transferring over a hundred and twenty processes into and out of it s facilities In the same period, Lonza US has had experience of transferring 35 processes into and out of it s facilities Since 2008 Lonza Spain had 6 transfers and Lonza Singapore is progressing 3 already Process Transfers to Mammalian Manufacturing - February 2011 Each site has dedicated MSAT (manufacturing science and technology) teams in place for these activities UK Forecast US Forecast Porriño Forecast Singapore Forecast UK Complete US Complete Porriño Complete Singapore Complete 10 There is a documented and proven technical transfer protocol
16 slide 16 Singapore facility construction and start-up Cell line creation Clinical manufacturing Process development Commercial manufacturing Build to buy
17 Lonza Singapore operations Facility 1 build to buy for Genentech/Roche Mammalian cell culture Manufacturing for commercial operations only Facility 2 typical Lonza CMO model Mammalian cell culture Process development Manufacturing for clinical development Manufacturing for commercial operations Cell therapy slide 17
18 slide 18 Lonza Facility 1 - build to buy model Large scale cell culture production facility dedicated for the production of Avastin for Genentech / Roche Genentech held an option to purchase the facility GMP operations in mid 2009 Staff of 300+ Roche exercised purchase option in Aug 2009
19 slide 19 Key principles design and build Lonza to design facility. Emphasis on leveraging Lonza s existing processes, equipment, design and operation for speed and costs Customer platform process can be part of design basis Facility purchase price is fixed. Customer gets visibility to challenge but Lonza assumes benefit / risk for actual facility cost Lonza to procure equipment / services, build and directly fund facility Customer to fund the capital based on agreed milestone achievements e.g. shell completion, mechanical completion successful pilot batch, successful PV series etc Lonza profit based on milestone achievement through to regulatory approval
20 Facility design and build approach Specification of equipment and systems per Lonza standard Use of previously qualified Lonza vendors for equipment fabrication, automation and building works Example considerable advantage in using Lonza automation platform (Emerson Delta V) which may not be Customer standard Customer would have every opportunity to review the quality and implementation of these in real life model (Lonza US, Singapore Facility 2) slide 20
21 Progress checks / quality assurance Lonza believes that customer should have every opportunity to review facility progress and adherence to agreed standard Progressive engineering design reviews at agreed milestones Review of selected vendors Mechanical completion inspections Regular engineering reviews to give customer assurance that Lonza is building to agreed specification Typically takes place progressively as construction nears completion Thorough due diligence at facility purchase slide 21
22 Key Principle operational enablement Lonza recruits and trains employees Validation, commissioning and facility start-up led by Lonza using Lonza quality systems All operating costs and net working capital costs (raw materials for runs etc) are reimbursed at cost on a recurring basis Lonza can provide additional support and services if required (e.g. tech transfer, pilot, engineering, PV batches) under supplemental agreements at agreed rates Migrate from Lonza quality systems after PAI, if desired slide 22
23 Typical milestone structure Milestones to be agreed based on Lonza s ability to construct, startup and deliver an approved facility Time based with an agreed window for completion e.g. FDA approval between June and December 2018 is 100% achievement, with sliding scale beyond this date Milestones to be split into capital and operational objectives slide 23
24 Key principle facility purchase Full commitment to facility purchase required, or In lieu of purchase, Lonza may consider entering into a long term take or pay supply agreement 100% capacity of facility for 10 years at an agreed batch price slide 24
25 slide 25 Singapore facility construction and start-up Cell line creation Clinical manufacturing Process development Commercial manufacturing Build to buy
26 slide 26 Lonza Facility 2 typical CMO model Cell culture production facility - multi product, campaign based, contract manufacturing, Multiple scales of operation 200L to 20,000L Multiple technology transfer programs in progress Currently 249 staff and rising to 300 when at full capacity
27 slide 27 Cell therapy and process development Cell culture facility for cell therapy operations on Level 2 Process development and analytical services operations on Level 1 Construction ongoing completion for operations in Q Cell therapy staff to 60 when at full capacity, R&D staff to 30+ at full capacity Space available for further expansion as required
28 Facility concept Cell culture production facility essentially copy the Lonza plant in Portsmouth, USA Commercially successful High success rate campaigns Multiple successful global, FDA and EMEA regulatory inspections Cell therapy production essentially copy the Lonza plant in Walkersville, USA PD services copies Lonza Slough, UK All plants leverage existing designs, know-how and documentation into the new facility design Incorporate all lessons learned from multiple years of GMP operation Flexible operations at a variety of scales Re-use proven process technology and quality systems, localize infrastructure Lonza Biologics Confidential slide 28
29 slide 30 Large scale cell culture production successfully completed on time & within budget Civil design, permitting Construction of shell Engineering design Order long lead equipment GO decision Construction fit out Start up/validation Employee training group 1 Employee training group 2 Pilot & engineering runs GMP production Submission & regulatory inspection Approval Approximately 3 years from Go decision point to full GMP operations
30 Singapore operations status Operational Process development Small scale non-cgmp pilot operations Large scale cgmp manufacturing for clinical/commercial supply at 5,000-20,000L scale In progress through Q Small scale cgmp manufacturing for clinical/commercial supply at 200-1,000L scale Q cgmp cell therapy operations Q slide 31
31 Start-up challenges & strategies: General First of its kind plant in Singapore Strategy Everything was being done for the first time at this scale Learning curve was steep for everyone involved employees, contractors, agencies Site leadership was an equal mix of Lonza expats & local employees Entire Lonza site leadership team migrated from Facility 1 to Facility 2 after divestment Vast majority of staff were local but some key technical positions from other Lonza sites - manufacturing, MSAT, engineering, QC Short term assignees from the Lonza network bridged any gaps Lessons learnt meticulously recorded and followed up between facilities slide 32
32 Start-up challenges & strategies: Design & engineering Design & Engineering Strategy Significant amounts of new / large scale equipment for the region Multiple locations for engineering and skid construction Time difference Designed to minimize learning curve the design around process equipment was kept intact compared to design as you go Identical naming convention, similar equipment design, flow paths etc Sequences were successful from the word Go Short term assignees from other sites were very familiar with the Singapore setup ease of commissioning, training Time difference was converted to an advantage. US operations provided support during Singapore nights ensured 24 x 7 coverage + leveraged on experience slide 33
33 Start-up challenges & strategies: Change management Changes impact schedule & cost Later and more frequent the changes, the more the impact Strategy Clear definition of scope and buy-in from all stakeholders Changes thereafter had to be defended by the change agent Changes proposed were critically evaluated for benefit vs. impact Common focus on deliverables and milestones Schedule and status was communicated regularly to the entire site via town hall meetings, C&V updates Rigorous oversight slide 34
34 Start-up challenges & strategies: Resources Manpower for operations (biotechnologist levels) Non-availability of local workforce trained in biologics manufacturing Knowledge of cgmp for biologics from existing Pharma industry Fresh graduates with engineering / biochemical backgrounds Strategy Utilised Singapore EDB s TAP and STRAT schemes to train local graduate employees Multiple waves sent to other Lonza sites (UK, US, Spain) for training in biologics for up to 18 months both for Facility 1 & 2 Manufacturing, QA, QC, MSAT and engineering Hired back in Singapore once successfully completed the program(s) Continued training and personal development slide 35
35 Start-up challenges & strategies: Resources Supervisory & middle management resources Limited supply of candidates capable of manning supervisory positions No previous opportunities to gain experience in biologics manufacturing Strategy Rigorous selection process focused on internal candidates Internal leadership training program established to facilitate the jump Targeted at manufacturing initially and expanded to other technical areas Intense training schedule + training stints in multiple Lonza mammalian sites + mentorship slide 36
36 Start-up challenges & strategies: Resources Manpower for start-up activities Need personnel familiar with systems to minimize snags / troubleshoot Training on equipment operation Strategy 100+ trained personnel were involved in walking systems down C & Q protocols were executed mostly in-house. Progressively increasing familiarity with systems walk-down, commissioning, executing protocols etc. Experienced short term assignees from other Lonza sites to lead and train significantly higher in Facility 1 - much lesser in Facility 2 the core team had progressed much further in terms of experience and confidence slide 37
37 Start-up challenges & strategies: Systems training Policies / SOPs / training / quality systems Quality systems, policies and SOPs need to be developed and made effective for training to be completed Critical to start-up and GMP commissioning Strategy Facility 1 and Facility 2 quality systems, policies and SOPs were harmonized with Lonza US Most of the process systems were identical Key advantage of the facility concept Training by short term assignees from Lonza US Lonza US for critical operations in Facility 1 Expertise of other sites such as Spain and UK utilised for training in Facility 2 critical operations slide 38
38 Start-up challenges & strategies: Go clean Setting up an EM program - disinfection Ineffective disinfection cycle or disinfectants could cause delays to the ability to maintain classification in clean rooms and consequently HVAC qualification and GMP commissioning Strategy Disinfection program modeled after Lonza US Disinfectant efficacy studies were conducted earlier on in Facility 1. Knowledge gained in Facility 1 was useful in Facility 2 Right choice of disinfectants and cycles No delays to GMP commissioning slide 39
39 Start-up challenges & strategies: Go clean Cleaning of GMP areas Steep learning curve for GMP cleaners Literacy needs vs. fit / willingness to work High turnover of cleaning crew Strategy Many training sessions + frequent refresher sessions Handholding of cleaning contractor to set up a sustainable program Contractor selection + training was initiated 2 months ahead of the first go-clean in Facility 2. GMP cleaning commenced more than a month before go-clean Float cleaners identified and trained from the general custodial cleaning crew. Incentive program to promote retention made to feel valued part of the overall team slide 40
40 Start-up challenges & strategies: Raw materials Raw material sourcing Challenge to establish supply chain, identify and qualify local sources Vendor qualification, generation of raw material specifications are typically time critical Long lead times for basic raw materials Strategy Supply chain was established early on with assistance from Lonza US Material review board met weekly to prioritize and review progress Entire flow of raw materials from BOM creation to release of raw material were clearly visible to all stakeholders for each item status was known and bottlenecks identified quickly Assistance from other Lonza sites alleviated schedule constraints for some materials slide 41
41 Overall lessons learnt Getting goals and expectations clear and agreed Making sure everyone is on the same page and each team understands its role and how it connects to site Ensuring transparency of the validation program planning and execution Connecting capital project team and the operational team to align expectations and standards Maintaining continuity and harmonisation with the rest of the Lonza network Quality procedures and site audit follow-ups need to be monitored carefully Operational practices can change / be upgraded Regular site to site updates all departments Short term assignees help slide 42
42 Overall lessons learnt Raw materials Start procurement early for the operational start-up Leverage the network to minimise lead times Leveraging the Lonza network Successful internal collaboration across the network was critical for success in all areas All the various groups within Lonza contributed the overall success of the projects in Singapore slide 43
43 Conclusion Lonza is able to support clients for mammalian biologics using a number of flexible business models Two facilities constructed and operational in Singapore Key was / is to leverage the global manufacturing network Standardise on as much as possible / only change what you must slide 44
We work with passion, using advanced technologies, to transform life science into new possibilities for our customers
We work with passion, using advanced technologies, to transform life science into new possibilities for our customers Full Year Results 27 January 2009 Stefan Borgas Chief Executive Officer Disclaimer
More informationOur passion is to deliver sustainable value to our customers Business Update: Third Quarter October 2007
Our passion is to deliver sustainable value to our customers Business Update: Third Quarter 23 October Stefan Borgas Chief Executive Officer Disclaimer Certain matters discussed in this presentation may
More informationOur passion is to deliver sustainable value to our customers 2008 First Half Results 23 July 2008
Our passion is to deliver sustainable value to our customers 2008 First Half Results 23 July 2008 Stefan Borgas Chief Executive Officer Disclaimer Certain matters discussed in this presentation may constitute
More informationA CMO s View on Platform Technologies
Pharma&Biotech A CMO s View on Platform Technologies A3P BioProduction 2013 BioPurification, Lyon, France Louise Elise-marie Ingram/ Seng Lonza /, Basel Biologics / 10. Mai / 182012 Jun 13 Disclaimer Certain
More informationWe work with passion, using advanced technologies, to transform life science into new possibilities for our customers
We work with passion, using advanced technologies, to transform life science into new possibilities for our customers Business Update: First Quarter 2009 23 April 2009 Stefan Borgas Chief Executive Officer
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationBusiness Update: First Quarter 2007
Conference Call, April 19 th, 2007 Business Update: First Quarter 2007 Stefan Borgas, CEO Disclaimer Certain matters discussed in this presentation may constitute forwardlooking statements. These statements
More informationPharma&Biotech. Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies
Pharma&Biotech Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies Elise-marie R. Beri / Lonza Seng Biologics /, Basel Inc / 10.
More informationThe Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics
The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics Visit of Alabama Biotech Oct 2014 Alain BERNARD Vice President GPS, UCB Technical Operations Tech Ops BioTech
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationLonza Capital Markets Day Staying Ahead. Marc Funk COO Lonza Pharma & Biotech. Capital Markets Day September 2018
Corporate Lonza Capital Markets Day 2018 Staying Ahead Marc Funk COO Lonza Pharma & Biotech Staying Ahead Lonza Capital Markets Day 2018 Agenda Outlook Lonza Pharma & Biotech overview Delivering on our
More informationPharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful
Pharma&Biotech ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and
More informationFuture Perspectives of Antibody Manufacturing
BioProduction 2005 Amsterdam Future Perspectives of Antibody Manufacturing John Birch Lonza Biologics Monoclonal Antibodies A Success Story Fastest growing segment of the pharmaceutical market Sales forecast
More informationLFB BIOMANUFACTURING YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING
YOUR CDMO PARTNER FOR MABS AND RECOMBINANT PROTEINS B IOMANUFACTURING COMMITMENT AND FLEXIBILITY LFB BIOMANUFACTURING is a medium-sized CDMO offering Bioproduction services, from an industrial facility
More informationCSL s Large Scale Cell Culture Facility
BioProcess Network 20 th October 2011 CSL s Large Scale Cell Culture Facility Tim Hughes Sr. Dir. Clinical Manufacturing CSL Objective How to maximise the opportunity to build a state-of-theart facility
More informationLONZA Q1 QUALITATIVE BUSINESS UPDATE 2019
LONZA Q1 QUALITATIVE BUSINESS UPDATE 2019 Contents Lonza Q1 2019 Corporate Overview Lonza Q1 2019 Segments Overview - Pharma Biotech and Nutrition - Specialty Ingredients Outlook 2019 and Mid-Term Guidance
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationSmall Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre
Small Scale Bio-Manufacturing for Clinical Trails; an Introduction to the Clinical Biotechnology Centre Keith Williams Business Development Manager - Clinical Biotechnology Centre CBC - Aims and Objectives
More informationProcess Transfer Excellence Basis for a fast and successful project
Process Transfer Excellence Basis for a fast and successful project Dr. Stefan Minning, Dr. Lars Dreesmann Boehringer Ingelheim Pharma GmbH & Co. KG Excellence in Biopharmaceutical Process Transfer Boehringer
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationProduct lifecycle management in one site
Product lifecycle management in one site Today s world provides multiple opportunities for a biopharma company. An aging global population and the prevalence of chronic and communicable diseases are creating
More informationManufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
More informationQ Qualitative Business Update Mid-Term Guidance Until End 2018
Pharma&Biotech Corporate Q1 2015 Qualitative Business Update Mid-Term Guidance Until End 2018 Richard Ridinger CEO Richard Ridinger / Lonza Group Ltd, Basel / 28 April 2015 Lonza Overview Q1 2015 Qualitative
More informationINTEGRATED PRODUCTION PLATFORMS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME PROCESS DEVELOPMENT, SCALE UP, GMP-COMPLIANT PRODUCTION AND CONSULTING INTEGRATED PRODUCTION PLATFORMS EVERYTHING STARTS WITH YOUR BRILLIANT
More informationFast Trak Services from molecule to market
GE Healthcare Fast Trak Services from molecule to market OPEN At the speed of Fast Trak Whether you re looking to launch a new molecule, enhance existing capacity, or bring biosimilars to emerging markets,
More informationPRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference**
PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference** The Future of Biologics Development and Manufacturing 20 April 2017 13:00 16:00 Big Sight Exhibition Center,
More informationUpstream mammalian cell processing challenges and prospects
BioProcess International Berlin, April 11-14, 2005 Upstream mammalian cell processing challenges and prospects John Birch Lonza Significance of Mammalian Cell Processes Commercial significance of biopharmaceutical
More informationFujifilm Diosynth Biotechnologies. General Introduction
Fujifilm Diosynth Biotechnologies General Introduction October 2016 Value from Innovation Safety information Accompanied by FDB staff at all times Fire alarm. Follow host to assembly point Toxic alarm.
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationAdvanced Microbial Protein Expression
Advanced Microbial Protein Expression Partners for Life Advancing tomorrow s medicines w A Biologics and Vaccines CDMO partner for your complete clinical journey Good science, experience and a quality
More informationLonza Nansha, China For Global Excellence in Advanced Chemical Synthesis
Pharma&Biotech Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis Lonza Guangzhou Nansha Ltd «Twenty-five years ago Lonza built one of the world s most advanced cgmp chemical manufacturing
More informationCorporate Presentation
Presentation July 2018 2018 Closer Than You Think 2018 2 Table of Contents Lonza at a Glance Full-Year Results 2017, Outlook 2018 and Mid-Term Guidance 2022 Deep-Dive into Segments Pharma & Biotech Specialty
More informationA Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody.
A Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody. Jeremy M Tong (presenting), Mark S Kettel, Edward M Perry, David J Pain, David M Valentine,
More informationEnsuring Quality & Regulatory Compliance when Collaborating with a Service Provider
DPT Thought Leadership Issue 2 Ensuring Quality & Regulatory Compliance when Collaborating with a Service Provider I N T R O D U C T I O N In recent years, the pharmaceutical industry has given greater
More informationRE: Draft Annex 2: Manufacture of Biological Medicinal Products for Human Use
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org 14 March 2008 European Commission Enterprise and Industry Directorate-General B-1049 Brussels Belgium BY EMAIL TO entr-gmp@ec.ec.europa.eu
More informationCREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO
CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO STATE-OF-THE-ART GMP FACILITIES Our sites in Jena and Halle (Germany) provide a complete range
More informationABL Europe s GMP manufacturing facility for viral vector production
ABL Europe s GMP manufacturing facility for viral vector production New Production Capacity for Viral Vectors Success Story ABL Europe GMP manufacturing of viral vectors from non-adherent cell cultures
More informationApplication of Disposable Technologies in Biopharmaceutical Manufacturing
BMD Summit, Disposables for Biopharm Production 13th December 2005 Reston, VA, USA Application of Disposable Technologies in Biopharmaceutical Manufacturing Martin Wrankmore, Continuous Improvement Lead,
More informationCalendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL
The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for
More informationTable of Contents. Welcome to Dishman. Our Mission. Our Focus: Client Satisfaction
Welcome to Dishman Our Mission Dishman Group continually invests in the global pharmaceutical industry, ensuring Dishman s business can provide pharmaceutical customers with high-value, high-quality products
More informationDevelopment from Bench to Clinic
Accelerating Novel Vaccine Development from Bench to Clinic Roger Lias. Ph.D. President Eden Biodesign, Inc Questions Questions are encouraged and can be asked by sending an email to: edenbiodesign@propelmg.com
More informationFRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS Close-up of large scale UF/DF control unit conditions and
More informationSummer Training Program In Industrial Biotechnology BiOZEEN, Bangalore
Summer Training Program In Industrial Biotechnology BiOZEEN, Bangalore BiOZEEN Summer Training Program in Industrial Microbiology & Fermentation Technology One small step can brighten your future Microbes
More informationOverview Rentschler Biotechnologie
Overview Rentschler Biotechnologie AusBiotech, Adelaide, 18.10.2011 Klaus B. Schoepe, PhD, SVP Client Relations - 1 - Our Mission As an independent leading, internationally operating service company, we
More informationLeading Supplier to the Life Science Industry
Leading Supplier to the Life Science Industry 2011 Full Year Results 25 January 2012 Rolf Soiron (Chairman) and Management Committee Forward-looking Statements Certain matters discussed in this presentation
More informationPharma&Biotech. XS Microbial Expression Technologies Optimize Productivity, Speed and Process Robustness
Pharma&Biotech XS Microbial Expression Technologies Optimize Productivity, Speed and Process Robustness Embracing Complexity Based on 30 years of innovation in microbial biotechnology, Lonza offers the
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationEden Biodesign ebook. Celebrating 10 Years of Success
Eden Biodesign ebook Celebrating 10 Years of Success Eden Biodesign ebook Chapter 1: Overview Chapter 2: Our History Chapter 3: Much More than a CMO Chapter 4: Key Milestones Chapter 5: About Eden Biodesign
More informationTABLE OF CONTENTS. 1.3 Industry Pricing Trends Recent Industry Pricing Changes Contractor Utilization Rates 1-5
TABLE OF CONTENTS Chapter 1: EXECUTIVE SUMMARY 1.1 Introduction 1-1 1.2 Participants Locations 1-3 1.3 Industry Pricing Trends 1-4 1.3.1 Recent Industry Pricing Changes 1-4 1.3.2 Contractor Utilization
More informationLONG R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications
Page 1 of 5 Page 1 of 5 Return to Web Version LONG R3IGF-I: An Insulin Alternative Exclusively for Cell Culture Applications By: Jennifer Fries, BioFiles 2009, 4.5, 14. LONG R 3 IGF-I is a recombinant
More informationContinuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities
Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Erik Fouts, Ph.D. VP and Site Head, Novato Operations 3-4 December ASTM E2968 14 Continuous
More informationWhitepaper. Small Molecule Vs Cell Therapy Clinical Trial Supply Chain. Martin Lamb, Executive Vice President for Sales and Marketing
Small Molecule Vs Cell Therapy Clinical Trial Supply Chain Page 1 Whitepaper Small Molecule Vs Cell Therapy Clinical Trial Supply Chain Martin Lamb, Executive Vice President for Sales and Marketing Small
More informationCONTRACTING CELL CULTURE
CONTRACTING CELL CULTURE BIOTECH EXPERIENCE Page 2 Professionals in proteins and antibodies Bayer HealthCare has more than 130 years of experience in developing and producing pharmaceuticals. An integral
More informationApplication of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols
Joint BWP/QWP/GMDP IWG Industry European Workshop on Lifecycle Management Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols 1 Outline Introduction: evolution of PACMP
More informationCOMPANY PROFILE. Dishman offers innovation, security of supply and value for money. Dishman Group. Research EARLY STAGE API. Preclinical.
COMPANY PROFILE Dishman is a global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and services. Dishman improves its customers businesses by providing
More informationTable of Contents. Presented by
Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com May 2017 TABLE OF CONTENTS
More informationAncillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach
USP/ISCT Workshop 2012 Seattle, WA, USA Ancillary Materials for Cell & Tissue Therapies Definitions, US Regulatory Approach, and USP s Risk-Tiered Approach Elizabeth Read, MD Head of Product Development
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationEfficient Project Management of Outsourced Biopharmaceutical Development and Manufacturing Programs
Efficient Project Management of Outsourced Biopharmaceutical Development and Manufacturing Programs Thomas C. Ransohoff and Howard L. Levine, Ph.D. BioProcess Technology Consultants Inc. Presented at IBC
More informationGlobal Integrated Solutions. Advanced Therapy Clinical Development and Commercialization
Global Integrated Solutions Advanced Therapy Clinical Development and Commercialization There There is is a patient patient waiting. waiting. Fisher BioServices ensures that your advanced therapy product
More informationCase Study: Examples Relating to the Quality Control of Cell-based Products
Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association
More informationRapid selection of high yielding GS-CHO cell lines using the GS expression system in a protein-free, chemically defined, animal component-free process
Rapid selection of high yielding GS-CHO cell lines using the GS expression system in a protein-free, chemically defined, animal component-free process David Mainwaring, Lonza Biologics. Introduction Chemically
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationTim Moore Global Head, Pharmaceutical Technical Operations Biologics, Genentech a member of the Roche Group
Ensuring the Supply of Quality Biopharmaceuticals: Integrated Manufacturing Network & Continual Improvement of Manufacturing Process Tim Moore Global Head, Pharmaceutical Technical Operations Biologics,
More informationRecent Opportunities & Challenges in microbial manufacturing
Recent Opportunities & Challenges in microbial manufacturing Elise Mous, CPhI Frankfurt, Oct 24 2017 Industry trend & challenge Customer perspective on outsourcing Key trend: Overall outsourcing growth
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More informationFinding the right partner for preclinical into phase I. Facts, Threats & Opportunities
Nuvisan Presentation Outsourcing and Clinical Trials DACH, 9th October 2018 Finding the right partner for preclinical into phase I Facts, Threats & Opportunities 9 October 2018 1 PASSIONATE PEOPLE FOR
More informationChromeleon CDS delivers efficiency gains and compliance and data integrity improvements to UK CRO/CMO
CASE STUDY Sterling Pharma Solutions Chromeleon CDS delivers efficiency gains and compliance and data integrity improvements to UK CRO/CMO Brian Alliston is currently a Data Integrity Expert and CDS Specialist
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationEffective Management and Operations of GXP Laboratories
Effective Management and Operations of GXP Laboratories Course Objective: Upon completion of this course, attendees involved in establishing and assuring that Good Laboratory / Good Manufacturing Practice
More informationContinuously Improving Bioprocesses: Biopharmaceutical Capabilities
Continuously Improving Bioprocesses: Biopharmaceutical Capabilities Pall Corporation A Legacy of Innovation Dr. David B. Pall Founded by Dr. David B. Pall in 1946, Pall Corporation has grown from a company
More informationBioProcess Technology Consultants, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994
, Inc. Helping Clients De-Risk Biopharmaceutical Development Since 1994 Who We Are The biopharmaceutical and biotherapeutic development experts We are a team of results-oriented professionals assisting
More informationThe Elite Provider. Cell & Gene. Therapy Manufacturing
The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists
More informationMDI Manufacturing Services
MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products
More informationDSM Biologics. DSM Brings Mammalian cgmp Manufacturing to Australia
DSM Biologics AusBioTech 2012 Melbourne October 31, 2012 Marc Goemans VP Global Marketing & Sales DSM Brings Mammalian cgmp Manufacturing to Australia Agenda Introduction Brisbane How do we serve Australian
More informationPosition1: Senior Scientist/Principal Scientist
Position1: Senior Scientist/Principal Scientist Field: Immunology, Immuno-Oncology Department: Discovery Biology : o Develop and conduct cell or immune based assays to support drug discovery in cancer
More informationBrazil: A Global Biotech Hub
Brazil: A Global Biotech Hub Single Use Devices Enables Bioprocessing for Domestic Biologics, Biosimilars, Export Mathew Cherian Ph.D. Director Pharmaceutical Development Hospira, Inc. USA Brazil s Potential
More informationServing Patients is a Privilege
Serving Patients is a Privilege This Privilege Comes with Significant Responsibilities Understanding Requirements for Data Integrity How to Develop a Data Integrity Program Including Data Integrity with
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationIntensification of a Perfusion Platform using Single-use XCell ATF Systems
Intensification of a Perfusion Platform using Single-use XCell ATF Systems Olaf Mol Sr. Bioprocess Scientist The world leader in serving science Global Footprint- Biologics Princeton, USA PD Center of
More informationMeeting sponsor s criteria : strategy to collaborate, engage and deliver
Meeting sponsor s criteria : strategy to collaborate, engage and deliver Frédérique Couttet Clinical Trial Manager 4th Annual Outsourcing in Clinical Trials Europe Brussels, Switzerland, May 21 22, 2014
More informationHow to rescue a clinical trial
How to rescue a clinical trial Clinical trial conduct is demanding and rigorous, especially in orphan indications where patient populations are small. Even well-qualified, specifically selected Contract
More informationENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL
Shaping the Future of Drug Development ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL Jim Baker Senior Vice President Clinical Research Services Cytel JIM BAKER Senior
More informationPhuse poster. Off shored, 5 years on (PP17)
Phuse poster Off shored, 5 years on (PP17) Author : Mr Bhupendra Mistry Company : Roche Products Ltd, UK 0. Introduction The aim of this poster is to share our experiences of creating and using a statistical
More informationBiopharmaceuticals A Regulatory Perspective
Biopharmaceuticals A Regulatory Perspective Maeve Lally Senior Pharmaceutical Assessor (Biologics) CASSS CMC Forum Killarney May 2017 Cead Mile Fáilte A hundred thousand welcomes 26/06/2017 2 Disclaimer
More informationAn Introduction to Double Dragon Consulting
An Introduction to Double Dragon Consulting www.doubledragonconsulting.com About DDC Our Experience: - All dosage forms, aseptic processes, API manufacture, OTC - Remediation of 483 observations, Warning
More information1. Clinical Program Manager (ideally based in greater Boston, MA, USA area)
Livzon Mabpharm, Inc ( 珠海丽珠单抗生物技术有限公司 ) a development stage biotech company, was jointly founded by two publically traded companies (Livzon Pharmaceuticals Group and JointCare). It focuses on the development,
More informationAssessing and Managing Strategic Risk for Next Generation Processes of Established Brands Eric R. Garr Associate Director, Global Product Development
Assessing and Managing Strategic Risk for Next Generation Processes of Established Brands Eric R. Garr Associate Director, Global Product Development and Supply Our Mission To discover, develop and deliver
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationICH Quality Implementation Working Group POINTS TO CONSIDER
ICH Quality Implementation Working Group POINTS TO CONSIDER ICH-Endorsed Guide for ICH Q8/Q9/Q10 Implementation Document date: 16 June 2011 International Conference on Harmonisation of Technical Requirements
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationFast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China
GE Healthcare Fast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China A case study Fast Trak Services Ongoing collaboration aims to accelerate biosimilar approval in China
More informationRobert Posgai Director of Materials Procurement, Biogen (BPOG)
Keynote Speaker Building the Foundations for Excellence in Biopharmaceutical Raw Material Supply Chain and Impact of Modality on Excipient Expectations Robert Posgai Director of Materials Procurement,
More informationOutsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing
Outsource or in-house? The evolving role of analytical services in pharmaceutical manufacturing By Impact Analytical Introduction About Impact Analytical Impact Analytical is a contract analytical testing
More informationibio, Inc. Holds Annual Meeting in College Station, Texas
April 7, 2016 ibio, Inc. Holds Annual Meeting in College Station, Texas NEW YORK, NY -- (Marketwired) -- 04/07/16 -- ibio, Inc. (NYSE MKT: IBIO) - Speaking to shareholders at the ibio, Inc. (NYSE MKT:
More informationTransferring a process to a contract
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2010, Vol. 30 No. 4 www.ispe.org Copyright ISPE 2010 This article presents a process transfer case study and the significance
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationGxP Auditing, Remediation, and Staff Augmentation
GxP Auditing, Remediation, and Staff Augmentation TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing 8
More information